Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer
Authors
Keywords
-
Journal
JOURNAL OF MEDICAL ECONOMICS
Volume 20, Issue 4, Pages 345-352
Publisher
Informa UK Limited
Online
2016-12-06
DOI
10.1080/13696998.2016.1269015
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Arguing (About) the Value of Cancer Care
- (2016) Ivo Abraham et al. Journal of the National Comprehensive Cancer Network
- Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review
- (2016) Mahdi Gharaibeh et al. PHARMACOECONOMICS
- Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer
- (2015) M Gharaibeh et al. BRITISH JOURNAL OF CANCER
- First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States–Based Cost-Effectiveness Analysis
- (2015) Daniel A. Goldstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Progress in the Treatment of Metastatic Pancreatic Cancer and the Search for Next Opportunities
- (2015) Andrew H. Ko JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
- (2015) Lowell E. Schnipper et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic Advances in Pancreatic Cancer: Miles to Go Before We Sleep
- (2015) T. Bekaii-Saab et al. JNCI-Journal of the National Cancer Institute
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- Therapeutic Advances in Pancreatic Cancer: Miles to Go Before We Sleep
- (2015) T. Bekaii-Saab et al. JNCI-Journal of the National Cancer Institute
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- Cost-effectiveness of systemic therapies for metastatic pancreatic cancer
- (2013) V.C. Tam et al. Current Oncology
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial
- (2012) Sophie Gourgou-Bourgade et al. JOURNAL OF CLINICAL ONCOLOGY
- Does Health-Related Quality of Life Improve for Advanced Pancreatic Cancer Patients Who Respond to Gemcitabine? Analysis of a Randomized Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
- (2011) Dorothy Romanus et al. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
- Projections of the Cost of Cancer Care in the United States: 2010-2020
- (2011) A. B. Mariotto et al. JNCI-Journal of the National Cancer Institute
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Estimating the Power of Indirect Comparisons: A Simulation Study
- (2011) Edward J. Mills et al. PLoS One
- Cancer treatment cost in the United States
- (2010) Florence K. Tangka et al. CANCER
- Use of Indirect and Mixed Treatment Comparisons for Technology Assessment
- (2008) Alex Sutton et al. PHARMACOECONOMICS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started